This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Inari Medical, Inc. (NARI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 82.61% and 5.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STERIS (STE) Set to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) fourth-quarter fiscal 2023 results are likely to reflect an impressive performance across the Healthcare and AST segments, with a gradual improvement in the supply chain.
STERIS (STE) Q3 Earnings Miss Estimates, Margins Down Y/Y
by Zacks Equity Research
Negative foreign currency and the impact of increased supply chain and inflationary costs hurt STERIS (STE) revenues in the fiscal third quarter.
Steris (STE) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of -9.01% and 4.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Hologic (HOLX) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 18.89% and 9.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
STERIS (STE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) hospital capital spending is expected to have remained robust in Q3, as evident from the healthcare backlog's recent trend.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE), led by strong segmental growth and the Cantel Medical acquisition.
STERIS (STE) Gains on New Orders, FX Impact Dents Growth
by Zacks Equity Research
STERIS (STE) is on track to achieve its stated goal of approximately $50 million of cost synergies in fiscal 2023.
STERIS (STE) Q2 Earnings Miss Estimates, Margins Increase
by Zacks Equity Research
Barring AST, poor reported revenue performance across three of STERIS' (STE) operating segments poses concerns.
Steris (STE) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of -0.50% and 1.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Silk Road Medical (SILK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of 34.09% and 10.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
STERIS (STE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) Dental arm revenues are expected to have been impacted somewhat by supply chain challenges.
Steris (STE) Down 0.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS' (STE) robust segmental performance and Cantel Medical buyout.
STERIS (STE) Gains From Cantel Buyout, Supply Chain Issue Stays
by Zacks Equity Research
Revenue growth at STERIS' (STE) Applied Sterilization Technologies is driven by increased demand from medical device and biopharma customers.
STERIS (STE) Q1 Earnings Match Estimates, EPS View Down
by Zacks Equity Research
STERIS' (STE) revenues at AST improve driven by increased demand from medical device and biopharma customers.
Steris (STE) Meets Q1 Earnings Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 0% and 5.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Abiomed (ABMD) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q1 sales.
McKesson (MCK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
What's in the Offing for QuidelOrtho (QDEL) in Q2 Earnings?
by Zacks Equity Research
QuidelOrtho's (QDEL) second-quarter results are likely to reflect strength across both its COVID and non-COVID businesses.
Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra (IART) Q2 Earnings Top, 2022 Adjusted EPS View Cut
by Zacks Equity Research
Integr's (IART) year-over-year growth in both the CSS and Tissue Technology segments buoys optimism.
Align Technology (ALGN) Q2 Earnings Lag Estimates, Margins Drop
by Zacks Equity Research
The dull underlying market situation, impacted by macro-economic environmental factors and lingering effects of COVID-19 variants in certain markets, impacts Align Technology's (ALGN) Q2 results.
AMN Healthcare (AMN) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
AMN Healthcare's (AMN) second-quarter results are likely to reflect solid demand across all its segments.